Readily Closes €1.6M Funding Round to Accelerate Diagnostics Development
Readily Diagnostics has successfully closed a €1.6M capital round, led by founders and existing shareholders and joined by new investors including the Beijer Foundation and LF Uppsala.
The funding will support product development and the build-out of in-house production capacity, accelerating Readily's path to bringing rapid infectious disease diagnostics to market.
New investors Beijer Foundation and LF Uppsala join existing backers Almi Invest, Uppsala University Invest, and co-founders Ulf Landegren and Ove Öhman in backing the company's next phase.
"We are very pleased to secure this funding as a show of confidence from our investors. It will enable us to build our in-house production of a cutting-edge diagnostic test and bring it to market faster," said Liza Löf, CEO of Readily Diagnostics.
Uppsala University Invest CEO Gunilla Lundmark added: "We are proud to be part of this dedicated investor consortium of valued local partners that will allow Readily to take the next necessary steps of developing the production capacity to enable a market introduction."